Results 231 to 240 of about 47,221 (287)
Risk of cardiovascular disease and death in patients with breast cancer receiving anthracycline-based therapy: A retrospective cohort study. [PDF]
PLoS OneLim YC, Lee YJ, Ha IH, Lee YS.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2005
Abstract Daunorubicin was the first anthracycline isolated, in France and Italy simultaneously in 1963, from the fermentation broth of an actinobacteria Streptomyces peucetius, and its antileukaemic properties in the clinic were rapidly acknowledged.
David, Hamilton, Gerald, Batist
+6 more sources
Abstract Daunorubicin was the first anthracycline isolated, in France and Italy simultaneously in 1963, from the fermentation broth of an actinobacteria Streptomyces peucetius, and its antileukaemic properties in the clinic were rapidly acknowledged.
David, Hamilton, Gerald, Batist
+6 more sources
Acta Oncologica, 1989
The major limitation of the usefulness of anthracyclines is the development of drug resistance. Most of the data related to anthracycline resistance has been obtained in experimental animal tumors or in cultured human cell lines. An important characteristic obtained in these models is the common finding of cross-resistance to a series of drugs ...
Bhushan, Alok +3 more
openaire +4 more sources
The major limitation of the usefulness of anthracyclines is the development of drug resistance. Most of the data related to anthracycline resistance has been obtained in experimental animal tumors or in cultured human cell lines. An important characteristic obtained in these models is the common finding of cross-resistance to a series of drugs ...
Bhushan, Alok +3 more
openaire +4 more sources
International Journal of Oncology, 1996
The genotoxicity and carcinogenicity data from in vitro and in vivo studies conducted during preclinical safety assessment of doxorubicin (DOXO), epirubicin (EPI) and idarubicin (IDA), are reviewed. The genotoxicity assays included a) gene mutation in Salmonella typhimurium with 5 tester strains; b) gene mutation in the V79 mammalian (lung) cell line ...
G, Mazue +10 more
openaire +2 more sources
The genotoxicity and carcinogenicity data from in vitro and in vivo studies conducted during preclinical safety assessment of doxorubicin (DOXO), epirubicin (EPI) and idarubicin (IDA), are reviewed. The genotoxicity assays included a) gene mutation in Salmonella typhimurium with 5 tester strains; b) gene mutation in the V79 mammalian (lung) cell line ...
G, Mazue +10 more
openaire +2 more sources
Expert Opinion on Drug Safety, 2011
Anthracyclines are widely prescribed anticancer agents that cause a dose-related cardiotoxicity, often aggravated by nonanthracycline chemotherapeutics or new generation targeted drugs. Anthracycline cardiotoxicity may occur anytime in the life of cancer survivors.
Pierantonio, Menna +5 more
openaire +2 more sources
Anthracyclines are widely prescribed anticancer agents that cause a dose-related cardiotoxicity, often aggravated by nonanthracycline chemotherapeutics or new generation targeted drugs. Anthracycline cardiotoxicity may occur anytime in the life of cancer survivors.
Pierantonio, Menna +5 more
openaire +2 more sources
Expert Opinion on Drug Safety, 2006
The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of anthracycline cardiotoxicity are described; an immediate pericarditis-myocarditis syndrome, an early onset chronic progressive CHF developing during or shortly after therapy and late-onset cardiotoxicity presenting years following treatment.
Robin L, Jones +2 more
openaire +2 more sources
The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of anthracycline cardiotoxicity are described; an immediate pericarditis-myocarditis syndrome, an early onset chronic progressive CHF developing during or shortly after therapy and late-onset cardiotoxicity presenting years following treatment.
Robin L, Jones +2 more
openaire +2 more sources
Current Medicinal Chemistry, 1998
This review summarizes the structure, the occurrence and the available data concerning the bioactivity of biosynthetic anthracyclines. The anthracyclines represent an important family of natural products produced by microorganisms of Streptomyces and related genera and include clinically useful agents for the medical treatment of human cancer.
F, Arcamone, G, Cassinelli
openaire +2 more sources
This review summarizes the structure, the occurrence and the available data concerning the bioactivity of biosynthetic anthracyclines. The anthracyclines represent an important family of natural products produced by microorganisms of Streptomyces and related genera and include clinically useful agents for the medical treatment of human cancer.
F, Arcamone, G, Cassinelli
openaire +2 more sources
Pediatric Cardiology, 1982
Life-threatening irreversible cardiomyopathy is a major complication of anthracycline therapy, particularly in the pediatric population. The pediatric cardiologist, in concert with the primary oncologist, should therefore play a major role in the care of patients receiving these agents and in clinical trials involving their use.
N L, Kobrinsky, N K, Ramsay, W, Krivit
openaire +2 more sources
Life-threatening irreversible cardiomyopathy is a major complication of anthracycline therapy, particularly in the pediatric population. The pediatric cardiologist, in concert with the primary oncologist, should therefore play a major role in the care of patients receiving these agents and in clinical trials involving their use.
N L, Kobrinsky, N K, Ramsay, W, Krivit
openaire +2 more sources
Morpholinyl anthracyclines: Option for reversal of anthracycline resistance
European Journal of Cancer and Clinical Oncology, 1990Anthracyclines are potent chemotherapeutic drugs, consisting of a 4-ring aglycon and an aminosugar, which both can be substituted. The most widely used are doxorubicin and daunorubicin, the parent drugs. The efficacy, toxicity and drug resistance may be related to different parts of the anthracycline molecule.
de VRIES, Elisabeth GE, Zijlstra, Jan G
openaire +2 more sources
2007
The clinical use of doxorubicin and other quinone-hydroquinone anticancer anthracyclines is limitedby a dose-related cardiotoxicity. Here, we review the correlation of cardiotoxicity of doxorubicinwith its peak plasma concentration and diffusion in the heart, followed by reductive bioactivation or oxidativeinactivation.
Pierantonio, Menna +3 more
openaire +2 more sources
The clinical use of doxorubicin and other quinone-hydroquinone anticancer anthracyclines is limitedby a dose-related cardiotoxicity. Here, we review the correlation of cardiotoxicity of doxorubicinwith its peak plasma concentration and diffusion in the heart, followed by reductive bioactivation or oxidativeinactivation.
Pierantonio, Menna +3 more
openaire +2 more sources